Patents by Inventor Ingrid W. Caras

Ingrid W. Caras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AL-1 neurotrophic factor treatments
    Patent number: 7067484
    Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
    Type: Grant
    Filed: August 18, 1997
    Date of Patent: June 27, 2006
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • AL-2 neurotrophic factor nucleic acid
    Patent number: 6696557
    Abstract: The present invention provides nucleic acids encoding AL-2 protein, host cells and vectors containing these nucleic acids, and methods for their use to produce AL-2 protein by recombinant DNA methods.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: February 24, 2004
    Assignee: Genentech, Inc.
    Inventor: Ingrid W. Caras
  • Decay accelerating factor (DAF) and nucleic acid encoding it
    Patent number: 6632634
    Abstract: Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.
    Type: Grant
    Filed: January 27, 1998
    Date of Patent: October 14, 2003
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, Michael A. Davitz, Victor Nussenzweig, David W. Martin, Jr.
  • Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
    Patent number: 6610296
    Abstract: The present invention provides methods of enhancing cognitive function in mammals by administering intracerebrally a homo-multimeric immunoadhesin molecule that contains the extracellular domain of AL-1, also known as ephrin-A5.
    Type: Grant
    Filed: January 2, 1996
    Date of Patent: August 26, 2003
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Novel methods of diagnosing macrophage developement related disorders, compositions, and methods of screening for macrophage developement modulators
    Publication number: 20030049722
    Abstract: The invention relates to the identification of nucleic acids and expression profiles involved in destructive macrophage (DM) development, and to the use of such expression profiles and nucleic acids in methods for identifying candidate agents which modulate this development.
    Type: Application
    Filed: March 15, 2000
    Publication date: March 13, 2003
    Inventors: Richard Murray, Ingrid W. Caras, Peter Hevezi, Keith Wilson
  • AL-2 neurotrophic factor
    Publication number: 20020142444
    Abstract: The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2 protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.
    Type: Application
    Filed: December 6, 2001
    Publication date: October 3, 2002
    Inventor: Ingrid W. Caras
  • Methods of using an AL-1 neurotrophic factor immunoadhesin
    Patent number: 6280732
    Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 28, 2001
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • AL-1 neurotrophic factor antibodies
    Patent number: 5798448
    Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: August 25, 1998
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Decay accelerating factor (DAF) and nucleic acids encoding it
    Patent number: 5763224
    Abstract: This application relates to nucleic acids encoding decay accelerating factor (hereinafter abbreviated as DAF), as well as vectors and cells which comprise such nucleic acids. Additionally, nucleic acids which encode variants of DAF, such as insertion, deletion or substitution variants, are described. This application also relates to the preparation of DAF in recombinant cell culture. In particular, it is concerned with the large scale manufacture of DAF suitable for pharmaceutical or diagnostic use.
    Type: Grant
    Filed: December 19, 1994
    Date of Patent: June 9, 1998
    Assignees: Genentech, Inc., New York University
    Inventors: Ingrid W. Caras, Michael A. Davitz, Victor Nussenzweig, David W. Martin, Jr.
  • Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
    Patent number: 5759775
    Abstract: Provided are nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders. The present invention provides methods to preferentially detect or amplify AL-1 nucleic acid in a sample using AL-1 nucleotide sequence probes.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: June 2, 1998
    Assignee: Genetech, Inc.
    Inventors: Ingrid W. Caras, John W. Winslow
  • Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
    Patent number: 5374548
    Abstract: Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: December 20, 1994
    Assignee: Genentech, Inc.
    Inventor: Ingrid W. Caras
  • Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
    Patent number: 5264357
    Abstract: Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.
    Type: Grant
    Filed: December 19, 1991
    Date of Patent: November 23, 1993
    Assignee: Genentech, Inc.
    Inventors: Ingrid W. Caras, Michael A. Davitz, Victor Nussenzweig, David W. Martin, Jr.
  • Membrane anchor fusion polypeptides
    Patent number: 5109113
    Abstract: Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.
    Type: Grant
    Filed: August 6, 1987
    Date of Patent: April 28, 1992
    Assignees: Genentech, Inc., New York University
    Inventors: Ingrid W. Caras, Michael A. Davitz, Victor Nussenzweig, David W. Martin, Jr.